Alliance - Newsletters

Home > Newsletters

Newsletters

Alliance E-News is the official newsletter of the Alliance for Clinical Trials in Oncology. The periodic newsletter focuses on current information about the Alliance, its policies and procedures, Group meetings and activities, and other topics of interest to Alliance members and others in the cancer research community. Press releases can also be viewed on this page.

2026

April

January

2025

October

September
- News Release: Can Digital Health Tools Help Younger Cancer Survivors Better Predict Future Health Risks?
- News Release: Alliance Webinar Highlights Latest Advances in Cancer Treatment

April
March
- News Release: FDA Approves Drug for Patients with Previously Treated Advanced Neuroendocrine Tumors Based on Results from Alliance CABINET Trial
- Spotlight on Alliance Trials
  A022101 (Limited metastatic colorectal cancer)
  A022104 (Advanced rectal cancer)
  A031701 (Invasive bladder cancer)
  A031803 (Non-muscular invasive bladder cancer)
  A032103 (Muscle invasive bladder cancer)
Feburary
- A Message from the NCTN Group Chairs: An Emphasis on the Importance of Research Funding
January
- Spotlight on Scientifc Annual Meeting: 2025 ASCO GI
- News Release: Blood Test from Alliance Trial Guides Use of Anit-Inflammatory Drug to Lower Colon Cancer Recurrence Risk

2024

December
November
- Dr. David Kozono Elected New Group Vice-Chair
October
- News Release: Alliance Group Statistician Co-Chairs Working Group Whose Recommendations Define "New Normal" Data Collection and Published in the Journal of the National Cancer Institute
- News Release: MyeloMATCH Precision Medicine Trials in Myeloid Leukemias Open to Patient Enrollment Across the U.S. and Canada
- 2024 Alliance Fall Hybrid Group Meeting Convenes October 30-November 1
- Alliance Features Five Trials During National Breast Cancer Awareness Month
  A011801 (COMPASS HER2 RD/Breast Cancer)
  A012103 (Early-stage Triple Negative Breast Cancer)
  A071701 (Genomically-guided Treatment in Brain Metastases)
  A191901 (Optimizing Endocrine Therapy)
  A222101 (Preventing Paclitaxel-associated Neuropathy)
- News Release: Alliance Appoints New Chief Operating Officer
September

August
- Spotlight in Alliance Trials
  World Lung Cancer Day
  >> Alliance A021901
  >> Alliance A081801
  >> Alliance A082002
  >> Alliance A082101
  >> Alliance A151216
  >> Alliance A211901
- Alliance Publications Committee: Transition and Progress
- General News and Announcements
  >> Alliance Research in the News & Publications
  >> Call for Nominations: Richard L. Schilsky CALGB Achievement Award
  >> Call ofr Nominations: Charles G. Moertel Lectureship Award
  >> Call for Applications: Daniel J. Sargent, PhD Memorial Fellowship in Innovative Clinical Trial Design and Methods
- PDF
May
- Updates on Precision Medicine Trials
  >> ALCHEMIST Trials
  David Kozono, MD, PhD - Study Chair, Alliance A151216
  Jacob Sands, MD - Study Chair, Alliance A081801
  >> ComboMATCH Trials
  Ardaman Shergill, MD - Study Chair, Alliance EAY191-A6
  Geoffrey Shapiro, MD, PhD - Study Chair, Alliance EAY191-A3
- Influencing New Standards of Cancer Care:
  VCU Massey Cancer Center MU-NCORP
  Asit Paul, MD, PhD - Site Principal Investigator for MU-NCORP Alliance Trials
- Evolution of Cancer Research Advocacy in Alliance
  Patty Spears, Vernal Branch, and Jane Permlmutter
  Alliance Patient Advocate Committee Leadership
- Spotlight in Alliance Trials
  National Bladder Cancer Awareness Month
  >> Alliance A031701
  >> Alliance A031702
  >> Alliance A031803
  >> Alliance A032002
  >> Alliance A032103
  National Brain Cancer Awareness Month
  >> Alliance A071401
  >> Alliance A071601
  >> Alliance A071701
  >> Alliance ABTC-1604
- General News and Announcements
  >> Alliance NCTN/NCORP/AFT at 2024 ASCO
  >> Alliance Research in the News & Publications
  >> 2024 Spring Hybrid Group Meeting
  >> 2024 Giants of Cancer Care Inductees
- PDF
March
- Message From The Group Statistician
- Breaking New Ground: Alliance Procedure-Based Therapy Program
- Update: Alliance Participant Engagement Portal (PEP)
- Spotlight on Alliance Trials
  >> Alliance A022004
  >> Alliance A022101
  >> Alliance A221805
  >> Alliance A031701
  >> Alliance A031803
  >> Alliance A032002
  >> Alliance A032103
- General News and Announcements
  >> Alliance Research in the News & Publications
  >> 2024 Spring Hybrid Group Meeting
- PDF
January
- Announcements
  >> Call for Nominations: Co-Chair, Alliance Publications Committee
  >> 2024 Alliance/AFT ASCO Abstract Submission Deadlines
  >> Alliance Foundation Special Allocation Funding Opportunity
- Press Release
  >> Alliance Study Shows Positive Results for Patients with Muscle-invasvie Urothelial Carcinoma
  >> Haystack Oncology and Alliance Foundation Trials collaborate to use Haystack MRD™ technology in phase II clinical trial for unresectable stage III NSCLC (AFT-57)
- Alliance in the News
  >> Clinical trial investigates how many months of immunotherapy are necessary to treat early-stage breast cancer (Alliance A012103 - OptimICE)

ARCHIVED NEWSLETTERS
From 2011 to 2023
https://allianceforclinicaltrialsinoncology.org/main/public/standard.xhtml?path=%2FPublic%2FNewsletters&rev=99334